journal
MENU ▼
Read by QxMD icon Read
search

Lancet Respiratory Medicine

journal
https://www.readbyqxmd.com/read/29778403/the-cf-sputum-induction-trial-cf-spit-to-assess-lower-airway-bacterial-sampling-in-young-children-with-cystic-fibrosis-a-prospective-internally-controlled-interventional-trial
#1
Katherine Ronchetti, Jo-Dee Tame, Christopher Paisey, Lena P Thia, Iolo Doull, Robin Howe, Eshwar Mahenthiralingam, Julian T Forton
BACKGROUND: Pathogen surveillance is challenging but crucial in children with cystic fibrosis-who are often non-productive of sputum even if actively coughing-because infection and lung disease begin early in life. The role of sputum induction as a diagnostic tool for infection has not previously been systematically addressed in young children with cystic fibrosis. We aimed to assess the pathogen yield from sputum induction compared with that from cough swab and single-lobe, two-lobe, and six-lobe bronchoalveolar lavage...
May 16, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29778402/cough-swabs-less-useful-but-induced-sputum-very-useful-in-symptomatic-older-children-with-cystic-fibrosis
#2
André Schultz, Daan Caudri
No abstract text is available yet for this article.
May 16, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29773327/immuno-oncology-in-malignant-pleural-mesothelioma
#3
Paul Baas, Maria Disselhorst
No abstract text is available yet for this article.
May 14, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29773326/tremelimumab-combined-with-durvalumab-in-patients-with-mesothelioma-nibit-meso-1-an-open-label-non-randomised-phase-2-study
#4
Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D'Incecco, Alessia Covre, Arthur Lewis, Marlon C Rebelatto, Riccardo Danielli, Maresa Altomonte, Anna Maria Di Giacomo, Michele Maio
BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first-line or second-line chemotherapy compared with placebo in the DETERMINE study. We aimed to investigate the efficacy and safety of first-line or second-line tremelimumab combined with durvalumab, an anti-PD-L1 monoclonal antibody, in patients with malignant mesothelioma. METHODS: In this open-label, non-randomised, phase 2 trial, patients with unresectable pleural or peritoneal mesothelioma received intravenous tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses...
May 14, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29759917/mica-pneumoconiosis-a-neglected-occupational-lung-disease
#5
LETTER
Subhabrata Moitra, Arghya Bandyopadhyay, Saibal Moitra
No abstract text is available yet for this article.
May 11, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29759916/occupational-dust-and-cigarette-smoke-exposure-might-link-rheumatoid-arthritis-to-copd
#6
LETTER
Dan Murphy, Katy Bellis, David Hutchinson
No abstract text is available yet for this article.
May 11, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29755003/populations-under-siege-and-in-prison-require-investment-from-syria-s-national-tuberculosis-programme
#7
LETTER
Aula Abbara, Hussam AlKabbani, Ibrahim Al-Masri, Zaher Sahloul, Annie Sparrow
No abstract text is available yet for this article.
May 10, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29735358/use-of-a-rare-disease-patient-registry-in-long-term-post-authorisation-drug-studies-a-model-for-collaboration-with-industry
#8
Diana Bilton, Noreen Caine, Steve Cunningham, Nicholas J Simmonds, Rebecca Cosgriff, Siobhán B Carr
No abstract text is available yet for this article.
May 4, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29706506/investigating-pneumonia-a-neglected-tragedy
#9
Ammara Mushtaq
No abstract text is available yet for this article.
April 26, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29705019/turning-parasites-into-friends-not-foes
#10
Peter Ranscombe
No abstract text is available yet for this article.
April 25, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29699819/lung-cancer-immunotherapy-biomarkers-refine-not-reject
#11
EDITORIAL
The Lancet Respiratory Medicine
No abstract text is available yet for this article.
April 23, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29699818/identification-of-remission-in-adult-onset-asthma
#12
Paula Busse, Michael E Wechsler
No abstract text is available yet for this article.
April 23, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29680638/corrections
#13
(no author information available yet)
No abstract text is available yet for this article.
April 18, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29661591/respiratory-health-in-italy
#14
Talha Burki
No abstract text is available yet for this article.
April 13, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29669702/targeting-alk-in-inflammatory-myofibroblastic-tumours
#15
Victor M Villalobos, D Ross Camidge
No abstract text is available yet for this article.
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29669701/crizotinib-in-patients-with-advanced-inoperable-inflammatory-myofibroblastic-tumours-with-and-without-anaplastic-lymphoma-kinase-gene-alterations-european-organisation-for-research-and-treatment-of-cancer-90101-create-a-multicentre-single-drug-prospective-non
#16
Patrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, Jean-Yves Blay, Sandra J Strauss, Silvia Stacchiotti, Piotr Rutkowski, Lars H Lindner, Michael G Leahy, Antoine Italiano, Nicolas Isambert, Maria Debiec-Rychter, Raf Sciot, Thomas Van Cann, Sandrine Marréaud, Axelle Nzokirantevye, Sandra Collette, Agnieszka Wozniak
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK)...
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29657094/advancing-towards-precision-medicine-in-ards
#17
Judith A Gilbert
No abstract text is available yet for this article.
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29653806/fake-medicines-fighting-on-all-fronts
#18
EDITORIAL
The Lancet Respiratory Medicine
No abstract text is available yet for this article.
April 10, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29650409/advances-in-ex-vivo-donor-lung-organ-care
#19
Allan R Glanville
No abstract text is available yet for this article.
April 9, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29650408/normothermic-ex-vivo-preservation-with-the-portable-organ-care-system-lung-device-for-bilateral-lung-transplantation-inspire-a-randomised-open-label-non-inferiority-phase-3-study
#20
Gregor Warnecke, Dirk Van Raemdonck, Michael A Smith, Gilbert Massard, Jasleen Kukreja, Federico Rea, Gabriel Loor, Fabio De Robertis, Jayan Nagendran, Kumud K Dhital, Francisco Javier Moradiellos Díez, Christoph Knosalla, Christian A Bermudez, Steven Tsui, Kenneth McCurry, I-Wen Wang, Tobias Deuse, Guy Lesèche, Pascal Thomas, Igor Tudorache, Christian Kühn, Murat Avsar, Bettina Wiegmann, Wiebke Sommer, Arne Neyrinck, Marco Schiavon, Fiorella Calebrese, Nichola Santelmo, Anne Olland, Pierre-Emanuel Falcoz, Andre R Simon, Andres Varela, Joren C Madsen, Marshall Hertz, Axel Haverich, Abbas Ardehali
BACKGROUND: Severe primary graft dysfunction (PGD) of grade 3 (PGD3) is a common serious complication following lung transplantation. We aimed to assess physiological donor lung preservation using the Organ Care System (OCS) Lung device compared with cold static storage. METHODS: In this non-inferiority, randomised, controlled, open-label, phase 3 trial (INSPIRE) recipients were aged 18 years or older and were registered as standard criteria primary double lung transplant candidates...
April 9, 2018: Lancet Respiratory Medicine
journal
journal
47869
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"